EREBRAL arteriovenous malformations (AVMs) are a tangle of blood vessels representing arterial-tovenous shunts. 18, 21, 27 Arteriovenous malformations occur in approximately 0.5% of the population; patients often present with hemorrhage or seizures. Two main features characterize AVMs. First, AVMs express abnormal vascular cell phenotypes ranging from relatively differentiated arteries and veins to maldeveloped thick-and thinwalled vessels. 18, 21 In the feeding arteries, a collagenous matrix often replaces vascular smooth muscle in the media. Second, AVMs demonstrate dysautoregulation of blood flow, resulting in regional disturbances in cerebral perfusion and ischemia. 22, 23, 28 Furthermore, the absence of normal high-resistance arteries leads to high intravascular pressures in the nidus, which is presumably the source of hemorrhage in most AVMs. Despite recent advances in diagnosis and treatment, AVMs remain clinically challenging, and the molecular basis for their pathophysiology remains elusive.
and abnormal phenotype observed in the vasculature of AVMs.
Materials and Methods

Patient and Control Specimens
Human AVMs were obtained from 25 patients at the time of operation. In eight patients, specimen size or presence of a large hemorrhagic component or necrosis precluded adequate tissue processing. Indications for surgery in the remaining 17 patients are outlined in Table 1 . In each case, one portion of the tissue was used for routine diagnostic histology and another portion was snap-frozen in isopentane submersed in liquid nitrogen and either sectioned into 6-to 10--thick sections for immunohistochemical staining or placed in sterile containers and stored at Ϫ70˚C for later extraction of RNA. The histopathology of the lesions was determined on fixed permanent sections stained with hematoxylin and eosin and MOVAT pentachrome for specific classification. Samples of the temporal lobe, surgically removed from other patients for the treatment of medically intractable epilepsy, were used as normal controls. All studies were approved by the Institutional Review Boards of the Cleveland Clinic Foundation and the University Hospitals of Cleveland.
Immunohistochemical Analysis of ET-1 Peptide Expression
Small blocks of brain tissue were mounted, frozen in liquid nitrogen, and cut into 10-m-thick serial sections. Thawed sections were washed in Dulbecco's phosphate-buffered saline (DPBS), fixed in 3.7% formaldehyde/DPBS for 5 minutes, washed again, and incubated with periodic acid to block endogenous peroxidase activity. Specimens were then incubated with 10% normal goat serum (NGS) to block nonspecific binding. Avidin and biotin blocking solutions were each used for 15-minute incubations to reduce background staining. Rabbit polyclonal antisera raised against human ET-1 were diluted 1:200 in DPBS/1% NGS and incubated with the specimens in a humidity chamber at room temperature for 1 hour. For negative controls, primary antibody was replaced with nonimmune rabbit serum at the same concentration of immunoglobulin G (IgG) or omitted. All specimens were processed in triplicate. Antibodies were then localized with biotin-labeled goat anti-rabbit IgG and peroxidase-labeled streptavidin. The cross reactivity of the primary antibody was as follows: ET-1, 100%; ET-2, 7%; ET-3, 7%; and proET-1, 17%. Sections were finally treated for 5 minutes with a freshly prepared diaminobenzidine substrate solution and washed in tap water. Hematoxylin was used for counterstaining. The slides were then dried and the specimens were successively dehydrated twice in 70%, 95%, and 100% ethanol for 3 minutes followed by xylene clearing. Specimens were mounted using Eukitt. Photomicrographs were exposed and developed identically so that a semiquantitative comparison of relative staining intensity was possible.
Extraction of RNA and Reverse Transcription-Polymerase Chain Reaction Analysis of ppET-1 Messenger RNA
The AVM vasculature was carefully and aseptically dissected (at 4˚C) from surrounding tissues, and specimens were minced in an RNase-free tissue grinder for extraction of total RNA. First-strand complementary (c)DNA was synthesized with 1 g RNA as a template and 2.5 mM of a downstream oligodeoxynucleotide primer (AACAACGTGCTCGGGAGTGTTGAC) complementary to a sequence in exon 3 of the human ppET-1 gene. 3 A reverse transcription (RT) reaction was performed (5 mM MgCl 2 , 10 ϫ polymerase chain reaction (PCR) buffer II, 1 U/l RNase inhibitor, 1 mM each of cyclic guanosine triphosphate, deoxyadenosine triphosphate, deoxythymidine triphosphate, and deoxycytidine triphosphate, and 2.5 U/l murine leukemia virus RT) at 42˚C for 30minutes, 52˚C for 30 minutes, 99˚C for 5 minutes, and 5˚C for 5 minutes. Following addition of an upstream primer (TTAAAG-GGCACTTGGGCTGAAGG) complementary to a DNA sequence in exon 1, PCR was performed for 2 minutes at 95˚C, 40 cycles of 2 minutes at 95˚C, annealing for 2 minutes at 50˚C, extending for 5 minutes at 72˚C, and one final extension for 7 minutes at 72˚C. Samples were vacuum dried, reconstituted in 20 l 1 ϫ Trisbuffered ethylenediamine tetraacetic acid loading buffer, separated on a 2% agarose gel with 0.5 g/ml ethidium bromide, and analyzed by scanning densitometry using computer imaging software.
Immunoassay for ET-1
Confluent AVM or normal brain endothelial cells placed in sixwell plates were incubated in Hank's balanced salt solution (without phenol red) with 25 mM 4-(2-hydroxyethyl)1 piperazine ethanesulfonic acid and 0.1% fetal bovine serum for 4 hours. One milliliter of culture supernatant was extracted with 1.5 ml acetone:1 M HCl:H 2 O (40:1:5 vol/vol/vol) and centrifuged at 4˚C for 20 minutes at 1200 G. The supernatant was dried down, reconstituted, neutralized to pH 7, and assayed immediately for ET-1. Immunoreactive ET-1 was measured in 100-l aliquots using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) with minor modifications. Absorbance readings from a media blank were subtracted from the experimental values. All assays were performed in duplicate.
Immunoprecipitation of ET A and ET B Receptors
Vasculature from AVM and normal brain were microdissected at 4˚C as described above. Tissue lysates were prepared by homogenizing 5 mg of tissue in 2 ml RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% deoxycholic acid, 2 mM ethylenediamine tetraacetic acid, 10 mM NaF, 10 g/ml leupeptin, 10 g/ml pepstatin, and 20 g/ml aprotonin). After centrifugation for 10 minutes at 1000 G, a 500-l aliquot of cell lysate was diluted 1:1 in RIPA buffer. The ET A or ET B receptor proteins were collected by immunoprecipitation with polyclonal antibodies raised against peptide epitopes of rat ET A or ET B and protein G plus agarose. Following the incubations, the immune complexes were rinsed three times with 1 ml RIPA buffer. The final pellet was suspended in 40 l 2 ϫ sodium dodecylsulfate (SDS) loading buffer, heated at 100˚C for 5 minutes and pelleted again in a microfuge for 5 minutes. A 40-l aliquot of the supernatant was loaded onto an 8 to 16% gradient SDS-polyacrylamide gel electrophoresis (PAGE) minigel. After electrophoresis, the proteins were transferred onto a nitrocellulose filter and blocked overnight in blocking buffer (3% bovine serum albumin, 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween-20). The transferred proteins were probed with the ET A or ET B receptor antibody diluted 1:400 in blocking buffer (1 hour at 25˚C) followed by a rabbit anti-sheep IgG conjugated to horseradish peroxidase diluted 1:5000 in block buffer (1 hour at 25˚C). After washing the filter 30 minutes in wash buffer, the ET A and ET B receptor proteins were detected using an enhanced chemiluminescent detection system.
Endothelial Cell Strains From AVMs and Normal Cerebrovasculature
Primary cultures of endothelial cells were isolated and characterized as previously described with minor modifications. 5 Briefly, microdissected and aseptically washed vessels were incubated for 10 minutes at 37˚C with 1 mg/ml type II collagenase, and the partially digested tissue was explanted on fibronectin-coated (1 g/cm 2 ) plates in MCDB 107, 15% fetal bovine serum, 90 g/ml heparin, and 150 g/ml endothelial growth supplement. At confluence the cells were subcultured, and passages 1 through 5 were used in these studies. The cells were characterized morphologically by light and electron microscopy according to cobblestone morphology and Weibel-Palade bodies, by immunofluorescent staining for factor VIII, and by uptake of acetylated low-density lipoprotein. All cell strains exhibited markedly positive reactions for the endothelial markers.
Statistical Analysis
Immunohistochemical staining for ET-1 was assigned a score from 1+ to 4+ according to increasing intensity by investigators blinded to the results. Significance between staining in normal and AVM specimens was calculated using the Mann-Whitney test. Statistical significance in other experiments was calculated using a t-test. The data presented are the mean Ϯ standard error of the mean; p Ͻ 0.05 is considered significant. Statistical analysis was performed using commercially available software.
Sources of Supplies and Equipment
Avidin and biotin blocking solutions were obtained from Vector Laboratories (Burlingame, CA); rabbit polyclonal antisera raised against human ET-1 (No. RIN6901) from Peninsula Labs (Belmont, CA); and biotin-labeled goat anti-rabbit IgG, peroxidase-labeled streptavidin, and diaminobenzidine substrate solution (DAB-C) from Kierkegaard and Perry Laboratories, Inc. (Gaithersburg, MD). Perkin Elmer (Norwalk, CT) provided all the materials used for the RT reaction. The polyclonal antibodies raised against peptide epitopes of rat ET A and ET B were obtained from AbProbe, Inc. (Portland, ME).
Miles Laboratories (Naperville, IL) provided the OCT-TissueTek II on which the blocks of brain tissue were mounted. Specimens were mounted using Eukitt provided by Calibrated Instruments, Inc. The double-antibody sandwich ELISA kit was purchased from R & D Systems (Minneapolis, MN) and the enhanced chemiluminescent detection system from Amersham (Arlington Heights, IL). Scanning densitometry was performed using Image (Version 1.55), which was provided by the National Institutes of Health. Statistical analysis was performed using InStat (Version 2.0) for Macintosh computers, obtained from GraphPad Software (San Diego, CA). Table 1 provides a summary of the characteristics of 17 patients at the time of surgery to remove AVM lesions. Presenting symptoms were hemorrhage, seizures, or headache. The AVMs were classified according to standard criteria of Spetzler and Martin. 27 The subjects were not biased as to race or ethnic origin, and their medical histories were unremarkable for vascular abnormalities. Four patients with Sturge-Weber syndrome underwent functional hemispherectomy for medically intractable epilepsy. For "normal" individuals without AVMs used as controls, we analyzed the cerebrovasculature of temporal lobes surgically resected for treatment of medically intractable epilepsy, which were histologically normal and showed no evidence of neoplasm.
Results
Study Group
Expression of ET-1 Peptide in AVMs
We examined cerebrovascular ET-1 expression by immunohistochemical investigation of fresh-frozen sections obtained from normal brain and from 17 patients with AVMs. As previously described, 14 the normal human cerebrovasculature expressed abundant levels of immunoreactive ET-1 in the endothelium (arrows, Fig. 1A ) and to a lesser extent in underlying smooth muscle. Immunostaining with nonimmune serum demonstrated that immunoreactivity was specific for ET-1 (Fig. 1B ). In contrast, the endothelium of AVMs completely lacked expression of ET-1 peptide ( Fig. 1C and E ). An absence of AVM ET-1 staining was observed in all 17 patients examined and was highly significant compared to normal individuals (p Ͻ 0.01). The ET-1 expression was lacking in all segments of the AVMs, including feeding arteries, nidus, and draining veins. Occasionally a gradient of increasing ET-1 expression was observed in distal portions of draining veins, but this was difficult to quantify (data not shown). Moreover, ET-1 peptide was not expressed in thin-walled vessels lacking underlying smooth muscle (Fig. 1C) or in thick-walled vessels (Fig. 1E) . Nonimmune antisera controls also displayed negative results ( Fig. 1D  and F) . These results strongly indicate that ET-1 peptide secretion is repressed in AVM lesions.
We next asked whether inhibition of ET-1 peptide secretion resulted from germline mutations or was specific for AVM lesions. Normal vessels upstream and downstream from AVMs were analyzed histologically for ET-1 peptide secretion. In all cases (four of four patients), ET-1 peptide secretion was normal in uninvolved vessels ( Fig.  2A and C) . The ET-1 immunostaining was positive in small vessels that lacked smooth muscle ( Fig. 2A) and in larger vessels containing smooth muscle (Fig. 2C) . Negative controls again demonstrated the specificity of the immunohistochemical analysis of ET-1 ( Fig. 2B and  D) . We therefore conclude that inhibition of ET-1 secretion does not result from germline mutations in the ET-1 gene, but instead results from factors specific to AVMs.
We next sought independent evidence for the specificity of ET-1 peptide repression in AVMs. If inhibition of ET-1 peptide secretion was a nonspecific consequence of vascular malformations, we reasoned that other intracranial malformations would also demonstrate lowered ET-1 secretion. We therefore examined ET-1 peptide expression in intracranial vascular malformations from patients with Sturge-Weber disease (Fig. 3) . Surprisingly, malformed vasculature from Sturge-Weber lesions (four of four patients) expressed higher amounts of ET-1 than normal vessels (arrow, Fig. 3A, p Ͻ 0.01 ). These results demonstrate that repression of ET-l peptide in AVMs is not a nonspecific consequence of vascular malformations.
Preproendothelin-I mRNA Levels in AVMs
To address the molecular mechanisms responsible for inhibition of ET-l secretion in AVMs, we asked whether ppET-1 mRNA was expressed in AVMs. A quantitative RT-PCR assay was established to measure steady-state ppET-1 mRNA in total RNA from microdissected segments of AVM vessels. Oligodeoxynucleotide primers were designed to span exons 1 and 3 of the ppET-1 gene to discriminate between products amplified from mRNA and from potential contamination with genomic DNA (Fig. 4A) . A single 372-bp product was specifically amplified from total RNA (Fig. 4B) ; we verified linearity of the assay with respect to the amount of input RNA (Fig.  4B and C) . In AVM RNA obtained from six of six patients, ppET-1 mRNA was essentially undetectable even though abundant amounts of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were amplified from the same samples ( Fig. 5A and B) . In contrast, ppET-I mRNA was readily detectable in RNA extracted from normal cerebrovasculature and was elevated in Sturge-Weber vascular malformations (Fig. 5A and B ). These results demonstrate that the ppET-1 gene in AVMs is repressed, consistent with the lack of ET-l peptide secretion.
Endothelin-1 repression in AVMs 
Expression of ET-I in Endothelial Cells Cultured From AVMs
To analyze the mechanisms of ppET-I gene repression in AVMs further, we asked whether repression was due to local factors in AVMs or was instead intrinsic to AVM endothelial cells. We thus sought to determine whether repression of the ppET-I gene was maintained when endothelial cells from AVMs were isolated and cultured. Endothelial cells cultured from normal cerebral vessels and umbilical veins secreted abundant amounts of ET-1 peptide into the culture supernatant (Fig. 6) . In contrast, endothelial cells cultured from AVM vessels secreted 10-fold less ET-I over the same time period (Fig. 6) . Identical results were observed in cell strains isolated from two different AVM patients. We also measured ppET-I mRNA levels in total RNA extracted from the same cultures. Preproendothelin-1 mRNA levels were considerably reduced in cultured AVM endothelial cells compared to normal controls (Fig. 7 A and B) . Densitometric analysis revealed that ppET-1 mRNA was 9.2-fold less abundant in AVM versus normal brain endothelial cell strains (Fig.  7B ). These results demonstrate that repression of the ppET-1 gene is an intrinsic phenotype of AVM endotheliurn and is preserved in culture.
LOW Levels of ET A Receptor in AVMs
Our data demonstrate that the ppET-1 gene is specifi- cally repressed in AVM endothelium. However, it is also possible that vascular cells in AVMs lack expression of ET,,, ET,, or both, and would thereby be less responsive to ET-1. To investigate this possibility, we immunoprecipitated ET, and ET, receptors from microdissected vascular segments of AVMs and normal cerebrovasculature. A single specific 39-kD band was immunoprecipitated with ET, and ET, antisera, and immunoprecipitation with nonimmune serum demonstrated that this band was specific (Fig. 8) . The AVM vasculature expressed markedly less immunoreactive ET A receptor than did normal control vessels. In contrast, AVMs and normal controls expressed .I. Neurosurg. / Volume 86 /January, 1997 similar levels of ET B receptor. Therefore, the AVM phenotype is also associated with decreased expression of ET A receptors and, presumably, with a concomitant decrease in ET-1 responsiveness.
Discussion
The molecular basis for the abnormal development and dysautoregulation of blood flow in AVMs remains elusive. In this study we addressed the hypothesis that abnormal secretion of endothelium-derived mediators, such as ET-1, might contribute to the phenotype and dysautoregulation of blood flow in AVMs. We found that the ppET-1 gene is specifically repressed in AVM endothelium. Loss of this important paracrine and autocrine peptide, which helps regulate function and phenotype of vascular cells, might contribute to the pathophysiology of AVMs.
The ppET-1 gene in humans encodes a 212-amino acid prohormone, which through proteolytic processing involving a unique endothelin-converting enzyme yields the active 21-amino acid peptide ET-1. Endothelial cells secrete ET-1 primarily from the basolateral surface. Secreted ET-1 binds to two classes of protein G-coupled receptors: ET A and ET B . 16 In vascular smooth muscle, pericytes, and fibroblasts, ET-1 binds primarily to ET A receptors to stimulate vasoconstriction and/or cell growth. Endothelial cells express ET B receptors and autocrine stimulation of these receptors by ET-1 leads to vasorelaxation and, in some cases, cell growth. The release of ET-1 from endothelial cells has been shown to induce a phenotypic switch of fibroblasts to vascular pericytes, 29 and ET-1 also controls cell development and differentiation. 1, 9, 11, 12 Thus, ET-1 has the capacity to regulate not only blood flow but also to control expression of genes in vascular cells. Deregulated expression of ET-1 has been implicated in a variety of vascular disorders involving both hemodynamic and structural changes in the vasculature.
The major finding of this study is that the endothelium of AVMs fails to secrete ET-1. Several lines of evidence suggest that inhibition of ET-1 was specifically associated with AVMs. First, inhibition of ET-1 secretion was observed only in the AVM vasculature. Secretion of ET-1 was normal in vessels upstream and downstream from the AVM lesion, suggesting that germline mutations do not account for this observation. Second, vascular malformations in Sturge-Weber disease, which display many of the same phenotypic properties of AVMs, actually secrete more ET-1 than normal cerebral vessels. These results demonstrate that inhibition of ET-1 secretion is not a nonspecific consequence of intracranial vascular malformations. Third, conditions of high blood flow (that is, pressure and shear stress) stimulate ET-1 secretion by endothelial cells in most vascular beds. 17, 32 The inability of AVM endothelial cells to secrete ET-1 in the face of high blood flow intrinsic to AVMs is further evidence that ET-1 secretion is specifically inhibited.
Our results support the notion that repression of the ppET-1 gene accounts for the lack of ET-1 peptide secretion by AVMs. Preproendothelin-1 mRNA was undetectable in total RNA isolated from AVM vasculature but was readily detectable in RNA isolated from normal cerebrovasculature. The complete lack of ppET-1 mRNA in AVM RNA is impressive given the extreme sensitivity of RT-PCR, which can produce amplicons from rare RNA transcripts in a single cell. Either repression of ppET-1 gene transcription or destabilization of mRNA transcripts could theoretically account for the lack of ppET-1 mRNA transcripts in AVMs. It is well established that expression of the ppET-1 gene is regulated in part at the level of transcription. 13, 14 Native ppET-1 mRNA transcripts are relatively unstable (the half-life is approximately 15 minutes) and would be difficult to detect without upregulation of ppET-1 transcription. 10 Therefore, it seems likely that transcriptional repression contributes to the lack of ET-1 secretion in AVMs, although this remains to be tested experimentally. We also showed that repression of the ppET-1 gene was maintained in cultured endothelial cells derived from AVMs. These results indicate that repression of ppET-1 is an intrinsic phenotype of AVM endothelial cells and is not due to factors in the AVM microenvironment.
We also showed that the AVM phenotype is associated with decreased expression of immunoreactive ET A receptors. The level of ET B receptors was equivalent in AVMs and normal vasculature. The ET A is the predominant receptor in vascular smooth-muscle cells; a decrease in ET A expression could have important consequences for ET-1 responsiveness in AVMs. For example, even though AVM endothelial cells do not secrete ET-1, small amounts of it might be available from the circulation or from conversion of big ET-1 to bioactive ET-1 by ectopic endothelinconverting enzymes. A lack of ET A expression on AVM endothelial cells would prevent ET-1-induced cellular changes by exogenous sources of ET-1 and would reinforce the biological consequences of ppET-1 gene repression in AVMs.
How might a lack of ET-1 secretion contribute to the pathophysiology of AVMs? Endothelin-1 is a potent vasoconstrictor peptide that regulates vasomotor tone. Normally, high-flow states stimulate ET-1 secretion, which in turn is thought to increase vasoconstriction and normalize flow. The inability of AVMs to secrete ET-1 might explain the constitutive high-flow condition of AVMs that contributes to bleeding and local ischemia with the arteriovenous shunt. A lack of ET-1 secretion might also contribute to the abnormal vascular morphology in AVMs. Experiments with targeted knockouts of the ppET-1 gene demonstrate an essential role for ET-1 in the development of nervous and vascular tissues. 1, 9, 11, 12 Emerging evidence also indicates that secretion of ET-1 by the endothelium helps direct the genetic programming of underlying vascular cells. 16, 26 For example, ET-1 directs expression of adhesion molecules on human brain microvascular cells, 20 and coculture experiments document an important role for ET-1 in regulating the growth 4, 30 and phenotype 29 of underlying vascular cells. It is thus interesting to speculate that local repression of ET-1 secretion might contribute to the abnormal vascular development that characterizes AVMs. Moreover, vascular smooth-muscle cells and pericytes prevent abnormal proliferation of endothelial cells. 24 Perhaps the ET-1-dependent absence of normal underlying vasculature and the concomitant loss of negative growth regulation of endothelial cells might contribute to the profusion of vessel growth that characterizes AVMs.
Although these studies are consistent with a role for ET-1 gene repression in the pathophysiology of AVMs, they also raise several questions. First, we do not know if repression of the ET-1 gene precedes formation of AVMs or if repression occurs after formation and contributes primarily to the hemodynamic abnormalities. Animal models for AVMs are nonexistent and therefore this is a difficult question to address experimentally. Second, we do not know if abnormal secretion of additional endotheliumderived mediators also contributes to the pathophysiology of AVMs. The ability to induce ppET-1 gene expression in these lesions might enhance our understanding of the role of ET-1. The AVM and normal cerebrovasculature were microdissected and homogenized in RIPA buffer. Polyclonal anti-peptide antisera raised against specific epitopes in rat ET A and ET B were used for immunoprecipitation. The immunoprecipitates were resolved by electrophoresis, transferred to nitrocellulose, and the same antibodies were used to localize ET A and ET B proteins using chemiluminescent detection as described in Materials and Methods. Reactions with nonimmune serum confirmed the specificity of the immunoprecipitation; the band at 55 kD is the heavy chain of sheep IgG. Identical results were observed in two independent experiments using different patient samples.
